IDH1 Antibody

IDH1 Antibody Datasheet

IDH1 Antibody Product Information

• Immunogen: Recombinant Human IDH1 protein (Catalog#12055-H08E)
• Antibody Type: Mouse Monoclonal Antibody ( Mouse mAb Service Platform )
• Clone ID: 03
• Ig Type: Mouse IgG1
• Formulation: 0.2 μm filtered solution in PBS with 5% trehalose
• Preparation: This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human IDH1 (rh IDH1; Catalog#12055-H08E; O75874; Met 1-Leu 414).

IDH1 Antibody Usage Guide

• Specificity: Human IDH1
• Flow Cytometry:
  

  Flow cytometric analysis of Human IDH1 expression in HepG2 cells. The cells were treated according to manufacturer's manual (BD Pharmingen™ Cat. No. 554714), and stained with Purified Mouse anti-IDH1 (12055-MM03, 1 μg/test), then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells.

  Flow cytometry was performed on a BD FACSCalibur flow cytometry system

  Please refer to www.sinobiological.com/Flow-Cytometry-FACS-Protocols-a-750.html for technical protocols.

• Storage: This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
  Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

IDH1 Antibody Background

Isocitrate dehydrogenases 1 (IDH1), one of the Isocitrate dehydrogenases, which catalyze the oxidative decarboxylation of isocitrate to α-ketoglutarate and reduce NAD (P)+ to NAD (P)H. This process involves oxidation of isocitrate to oxalosuccinate, with NAD (P)H as the electron acceptor, followed by decarboxylation of oxalosuccinate to form α-ketoglutarate. IDH1 and IDH2 function at a crossroads of cellular metabolism in lipid synthesis, cellular defense against oxidative stress, oxidative respiration, and oxygen-sensing signal transduction. IDH1 and IDH2 mutations are usually heterozygous in cancer, and they appear to confer a neomorphic enzyme activity for the enzymes to catalyze the production of D-2-hydroxyglutarate. IDH1 is highly expressed in the mammalian liver and moderately expressed in other tissues. It contains a C-terminal tripeptide peroxisome targeting signal 1 sequence. Isocitrate dehydrogenase 1 (IDH1) mutations have recently been identified as early and frequent genetic alterations in astrocytomas, oligodendrogliomas, and oligoastrocytomas, as well as secondary glioblastomas, whereas primary glioblastomas very rarely contain IDH1 mutations.

References

1. Reitman ZJ. et al., 2010, J Natl Cancer Inst. 102 (13): 932-41.
2. Gabriel JL. et al., 1986, Metabolism. 35 (7): 661-667.
3. Jennings GT. et al., 1994, J Biol Chem. 269 (37): 23128-23134.
4. Takano S. et al.. 2011, Brain Tumor Pathol. 28 (2): 115-23.